Get started
Author

B. Doger de Spéville

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 + advanced non-small cell lung cancer
2022 · George R Blumenschein, Siddhartha Devarakonda, et al. · Journal for ImmunoTherapy of Cancer · 55
PDF
Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era
2021 · Bernard Doger de Spéville, Victor Moreno · Clinical Cancer Research · 24
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.
2023 · Bernard Doger de Spéville, Enriqueta Felip, et al. · Journal of Clinical Oncology · 13
1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study
2023 · A. Calles Blanco, A.F. Navarro Mendivil, et al. · Annals of Oncology · 10
PDF
11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
2023 · M. Majem, M.D. Forster, et al. · Journal of Thoracic Oncology · 10
PDF
Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors
2022 · E. Garralda, V. Moreno, et al. · European Journal of Cancer · 10
PDF
LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
2024 · A.J. Montero, A. Giordano, et al. · Annals of Oncology · 9
PDF
1318MO First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)
2023 · J.K. Rotow, S.N. Waqar, et al. · Annals of Oncology · 9
PDF
977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C NSCLC
2025 · D.S.W. Tan, E. Pons-Tostivint, et al. · Annals of Oncology · 8
652P BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
2024 · O. Reig Torras, L. Crouzet, et al. · Annals of Oncology · 7
PDF
LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1
2024 · C.A. Kristensen, R. Metcalf, et al. · Annals of Oncology · 7
Reacción cutánea mano-pie por regorafenib
2015 · P. Espinosa Lara, C. Bueno Muiño, et al. · Actas Dermo-Sifiliográficas · 6
PDF
647P EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
2024 · E. Fontana, J.S. Wang, et al. · Annals of Oncology · 5
PDF
654P Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
2024 · B. Doger de Spéville, M. Mckean, et al. · Annals of Oncology · 5
PDF
1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
2023 · E. Carcereny, E. Felip, et al. · Annals of Oncology · 5
PDF
96P: Enhanced anti-tumor activity of zelenectide pevedotin in patients (pts) with non-small cell lung cancer (NSCLC) with NECTIN4 gene amplification (amp)
2025 · L. Verlingue, N. Klümper, et al. · Journal of Thoracic Oncology · 4
PDF
1367P JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study
2022 · E. Calvo, B. Doger de Spéville, et al. · Annals of Oncology · 4
PDF
Hand-Foot Skin Reaction to Regorafenib
2015 · P. Espinosa Lara, C. Bueno Muiño, et al. · Actas Dermo-Sifiliográficas · 4
PDF
2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
2023 · P. Grivas, S. Sridhar, et al. · Annals of Oncology · 3
PDF
1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
2023 · R. Geva, M. Vieito Villar, et al. · Annals of Oncology · 3
PDF
887P Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
2023 · C. Le Tourneau, Z. Takacsi-Nagy, et al. · Annals of Oncology · 3
PDF
278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer
2020 · George Blumenschein, Siddhartha Devarakonda, et al. · Regular and Young Investigator Award Abstracts · 3
1073TiP A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
2024 · T.C. Hernandez Guerrero, B. Doger de Spéville, et al. · Annals of Oncology · 2
PDF
675 TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
2022 · Irene Brana, Valerii Cheshuk, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts
2022 · M.G. Krebs, M. Majem Tarruella, et al. · Annals of Oncology · 2
Works count: 51
Citation count: 220
H-index: 8
I10-index: 6
Year
Topic
Type